Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$57.45M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
1309.5%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$165.1M
Q3 2024
Cash
Q3 2024
P/E
-1.953
Nov 29, 2024 EST
Free Cash Flow
-$47.85M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021
Revenue $0.00 $0.00 $210.0K
YoY Change -100.0%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021
Revenue $0.00 $0.00 $210.0K
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021
Selling, General & Admin $7.518M $5.504M $3.896M
YoY Change 36.59% 41.27%
% of Gross Profit
Research & Development $30.29M $23.69M $8.370M
YoY Change 27.87% 183.01%
% of Gross Profit
Depreciation & Amortization $373.0K $342.0K $145.0K
YoY Change 9.06% 135.86%
% of Gross Profit
Operating Expenses $37.81M $29.19M $12.27M
YoY Change 29.52% 137.99%
Operating Profit
YoY Change

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021
Interest Expense $979.0K $114.0K $2.000K
YoY Change 758.77% 5600.0%
% of Operating Profit
Other Income/Expense, Net $525.0K $1.368M $2.867M
YoY Change -61.62% -52.28%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021
Pretax Income -$36.31M -$27.71M -$9.187M
YoY Change 31.02% 201.62%
Income Tax
% Of Pretax Income
Net Earnings -$36.31M -$27.71M -$9.187M
YoY Change 31.02% 201.62%
Net Earnings / Revenue -4374.76%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.42 -$1.08 -$0.36

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021
Cash & Short-Term Investments $82.55M $48.34M $25.71M
YoY Change 70.75% 88.07%
Cash & Equivalents $82.55M $48.34M $25.71M
Short-Term Investments
Other Short-Term Assets $2.731M $330.0K $236.0K
YoY Change 727.58% 39.83%
Inventory
Prepaid Expenses
Receivables $8.000K $333.0K $1.495M
Other Receivables $104.0K $213.0K $248.0K
Total Short-Term Assets $85.39M $49.22M $27.68M
YoY Change 73.49% 77.79%
Property, Plant & Equipment $1.231M $1.579M $1.060M
YoY Change -22.04% 48.96%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.000K $55.00K $50.00K
YoY Change -89.09% 10.0%
Total Long-Term Assets $1.237M $1.634M $1.110M
YoY Change -24.3% 47.21%
Total Assets $86.63M $50.85M $28.79M
YoY Change
Accounts Payable $1.074M $1.606M $600.0K
YoY Change -33.13% 167.67%
Accrued Expenses $4.536M $3.954M $1.210M
YoY Change 14.72% 226.78%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.610M $5.560M $1.810M
YoY Change 0.9% 207.18%
Long-Term Debt $9.861M $9.465M $0.00
YoY Change 4.18%
Other Long-Term Liabilities $1.352M $2.000M $1.299M
YoY Change -32.4% 53.96%
Total Long-Term Liabilities $11.21M $11.47M $1.299M
YoY Change -2.2% 782.6%
Total Liabilities $16.82M $17.03M $3.109M
YoY Change -1.19% 447.6%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $112.2 Million

About Alto Neuroscience, Inc.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. The company is headquartered in Mountain View, California and currently employs 88 full-time employees. The company went IPO on 2024-02-02. The firm is focused on redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. Through insights derived from the Company’s scalable and proprietary Precision Psychiatry Platform, which applies rigorous data science and robust analytics to data gathered by neurocognitive assessments, electroencephalography, and wearable devices, the Company aims to discover brain-based biomarkers to better identify which patients are more likely to respond to its novel product candidates. Its pipeline consists of five clinical-stage assets, such as ALTO-100, ALTO-202, ALTO-300, ALTO-101, and ALTO-203, which target depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers. Its pipeline also includes novel drug candidates in depression, post-traumatic stress disorder (PTSD), and other mental health conditions.

Industry: Pharmaceutical Preparations Peers: Aquestive Therapeutics, Inc. Atea Pharmaceuticals, Inc. biote Corp. ELI LILLY & Co Esperion Therapeutics, Inc. EyePoint Pharmaceuticals, Inc. Revance Therapeutics, Inc. Xeris Biopharma Holdings, Inc.